ÂÜÀòÂÒÂ×

Sara Weymer has over 20 years of experience in clinical research and drug development. She most recently served as Executive Director and Head of Clinical Operations at Fate Therapeutics. While at Fate, Sara oversaw the clinical implementation of 9 Fate-sponsored INDs and 6 Investigator-initiated INDs across 8 development programs. During this time, Sara had the opportunity to advance the clinical development of IPSC-derived NK and T-cell therapies in various hematologic and solid tumor indications.

Prior to that, Sara was responsible for clinical and regulatory operations at ZZ Biotech. While at ZZ Biotech, Sara led the clinical development of the company’s lead acute stroke drug candidate from the first-in-human study through the Phase 2 clinical study.

Earlier in her career, Sara acquired experience in various types of development organizations, starting at Parexel and progressing to manage clinical study teams at Biogen. She has overseen studies from Phase 1 through Phase 3, across various disease areas and drug modalities, including small molecule development in oncology.